Guggenheim raised the firm’s price target on Kymera Therapeutics (KYMR) to $52 from $45 and keeps a Buy rating on the shares. The firm is updating estimates to reflect Q3 financial results and updated cash runway and removing KT-253 and KT-333 from its model while adjusting estimates for KT-621 and KT-295 after the company business update included the deprioritization of its clinical stage oncology portfolio as part of the company’s “proclaimed shift” towards focusing investments on its immunology programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KYMR:
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
- Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift
- Kymera Therapeutics files automatic mixed securities shelf
- Kymera Therapeutics reports Q3 EPS (82c), consensus (84c)
- Kymera doses first patient in Phase 1 trial of KT-621
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
